The agreement between Unilife and Flextronics will support accelerating commercial demand from a multitude of pharmaceutical customers who are seeking to leverage Unilife’s products and services to enhance and differentiate their injectable biologics, drugs and vaccines. In addition to Unilife fully utilizing its own FDA-registered manufacturing facilities in York, PA, Flextronics will serve as a secondary source of supply to Unilife and its pharmaceutical customers.
“This strategic alliance will further enhance our supply chain and maximize efficiencies by aligning our own production capacity and scale-up capability with Flextronics’ proven manufacturing expertise and established global size,” said Dr. Ramin Mojdeh, president and COO of Unilife. “Flextronics is a leading and trusted provider of supply chain solutions for the pharmaceutical industry, and has long-term relationships with many current and prospective Unilife customers. We look forward to leveraging the power of Flextronics and their global manufacturing capabilities to further enhance Unilife’s own supply chain network and generate attractive manufacturing and supply chain efficiencies and robustness. Additionally, this partnership allows for the most efficient capital investment strategy to support our rapidly growing demand.”
“Flextronics is proud to collaborate and provide supply chain solutions to Unilife,” said Mark Kemp, president of Flextronics Medical. “We believe Unilife has created an exciting product portfolio that has significant potential to optimize the safe, simple and convenient delivery of injectable biologics, drugs and vaccines. We look forward to aligning our established, well-known supply chain solutions with Unilife’s market-leading products and services to meet the long-term needs of pharmaceutical and biotechnology companies.”